Press Releases

 Filter by Provider

FB Financial Corporation (“FB Financial”) (NYSE: FBK), the parent company of FirstBank, and Southern States Bancshares, Inc. (“Southern States”) (Nasdaq: SSBK), the parent company of Southern States Bank, jointly announced their entry into a definitive merger agreement pursuant to which Southern States will be merged with and into FB Financial.

Air Industries Group (“Air Industries”) (NYSE American: AIRI), a leading manufacturer of precision components and assemblies for large aerospace and defense prime contractors, today announced preliminary unaudited financial results for the calendar year ended December 31, 2024. The Company also reported record levels of new business and backlog and noted it will utilize the automatic 15-day extension to file its Annual Report on Form 10-K for the year ended December 31, 2024.

TPG RE Finance Trust, Inc. (NYSE: TRTX) (“TRTX” or the “Company”) announced today that it closed on Friday, March 28, 2025 TRTX 2025-FL6, a $1.1 billion managed Commercial Real Estate Collateralized Loan Obligation (“CRE CLO”). The Company placed $962.5 million of investment grade securities with institutional investors, providing TRTX with term financing on a non-mark-to-market, non-recourse basis. TRTX 2025-FL6 includes a 30-month reinvestment period, an advance rate of 87.5%, and a weighted average interest rate at issuance of Term SOFR plus 1.83%, before transaction costs. In connection with TRTX 2025-FL6, TRTX redeemed on March 17, 2025 TRTX 2019-FL3, a CRE CLO which had approximately $114.6 million of investment grade securities outstanding. The issuance of TRTX 2025-FL6 and the redemption of TRTX 2019-FL3 resulted in net cash proceeds to the Company of approximately $191.0 million for investment and other corporate purposes.

Recognizing Women Who Influence Change, Innovation and Standards of Excellence in Mid-Market Companies

Statement Pursuant to Section 19(a) of the Investment Company Act of 1940

AstraZeneca’s IMFINZI® (durvalumab) in combination with gemcitabine and cisplatin as neoadjuvant treatment, followed by IMFINZI as adjuvant monotherapy after radical cystectomy (surgery to remove the bladder) has been approved in the US for the treatment of adult patients with muscle-invasive bladder cancer (MIBC).

ABEC, a global leader in engineered solutions and services for biotech manufacturing, has introduced its Advanced Therapy Bioreactor (ATB™) – a revolutionary platform poised to transform cell expansion for Advanced Therapy Medicinal Products (ATMPs). Designed to overcome the limitations of currently available systems, the ATB™ delivers unprecedented process control and scalability from bench to commercial scale.

Yum! Brands, Inc. (NYSE: YUM) today announced that David Gibbs, Chief Executive Officer, has informed the Board of Directors of his intention to retire from the Company in the next year.

D-Wave Quantum Inc. (NYSE: QBTS) (“D-Wave” or the “Company”), a leader in quantum computing systems, software, and services, and Ford Otosan, a joint venture between Ford Motor Company and Koç Holding in Turkey, today announced that the vehicle manufacturer has deployed a hybrid-quantum application in production, streamlining manufacturing processes for its Ford Transit line of vehicles. The application, which uses D-Wave’s annealing quantum computing technology, has improved vehicle production sequencing at Ford Otosan, a powerful demonstration of quantum computing’s real-world impact in automotive manufacturing.

Statement Pursuant to Section 19(a) of the Investment Company Act of 1940

A team of research industry veterans, led by Tod Johnson, longtime leader and former Executive Chairman of The NPD Group, current Chair of Circana, current Chair of CivicScience, and founder of Media Metrix, today announced the launch of Tenetic with full capabilities in over 200 local U.S. markets and nationally. From launch, the platform is processing trillions of consumer behavioral attributes across hundreds of millions of U.S. consumers, delivering actionable insights for media companies and advertising agencies.

Kairos Pharma, Ltd. (NYSE American: KAPA), a clinical-stage biopharmaceutical company (the “Company’”), announces the completion of the safety lead-in of its Phase 2 clinical trial of ENV105 for the treatment of metastatic, castration-resistant prostate cancer. The trial, titled, “Phase II study of Apalutamide with Carotuximab (ENV105) in Metastatic, Castration Resistant Prostate Cancer,” began with the safety lead-in, which combined apalutamide, a standard of care for prostate cancer, with the Company’s compound ENV105.

D-Wave Quantum Inc. (NYSE: QBTS) (“D-Wave” or the “Company”), a leader in quantum computing systems, software, and services, and the pharmaceutical division of Japan Tobacco Inc. (“JT”) today announced the completion of a joint proof-of-concept project that used quantum computing technology and artificial intelligence (AI) in the drug discovery process. JT and D-Wave enhanced large language models (LLMs) with a quantum-hybrid workflow to increase their generative capabilities and enable JT to produce novel, more "drug-like" molecular structures beyond those found in the training datasets for the quantum-hybrid generative AI system.

Statement Pursuant to Section 19(a) of the Investment Company Act of 1940

Audax Private Equity (“Audax”), a capital partner to middle market companies, announced today that it has acquired a majority stake in Lanter Delivery Systems (“Lanter”) from Equity Group Investments (“EGI”), the private investment firm founded by Sam Zell. Terms of the deal were not disclosed.

D-Wave Quantum Inc. (NYSE: QBTS) (“D-Wave” or the “Company”), a leader in quantum computing systems, software, and services, today announced several initiatives designed to increase adoption and deployment of its commercial quantum optimization offering. At the Company’s Qubits 2025 user conference, D-Wave introduced updates to its hybrid quantum solvers and expanded use cases, reflecting increased demand for quantum optimization solutions from end users, independent software vendors (ISVs), system integrators (SIs), and resellers.

TJC, L.P. (“TJC”), announced today that an affiliate of The Resolute Fund VI, L.P. (“Resolute VI”) has closed the acquisition of L3Harris Technologies (NYSE:LHX) Commercial Aviation Solutions business (“CAS,” or the “Company”) for $800 million.

Seaport Therapeutics (“Seaport” or the “Company”), a clinical-stage biopharmaceutical company that is advancing novel neuropsychiatric medicines with a proven strategy and team, today announced that members of its management team will participate in the following upcoming investor conferences:

Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced that Chen Schor, President and Chief Executive Officer, will participate in a panel at the Canaccord Genuity Horizons in Oncology Virtual Conference being held April 7, 2025.

KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), today announced that the Company will participate in a fireside chat at the 24th Annual Needham Virtual Healthcare Conference on Monday, April 7, 2025 at 1:30 p.m. ET.

Element 1® (e1NA) has received a guaranteed five-year, multi-unit purchase order from a major North American partner for its L18-PSA methanol-to-hydrogen generator. The total value of the order is more than $5.3 million, with the first L18-PSA units scheduled for delivery later this year. Under the terms of the agreement, e1NA grants exclusive L18-PSA distribution rights to the buyer within the US, Canada, Mexico, and the UK. This partnership marks a significant step forward in reducing the price of compressed hydrogen while increasing security of supply.

Wolters Kluwer Tax & Accounting (TAA), a global leader in professional information, software solutions, and services, today announced that Simon Hjortsberg, the company's Manager of Business Intelligence, will be a speaker at the Microsoft Fabric Community Conference. The anticipated event will take place from March 31 to April 3, 2025, at the MGM Grand Las Vegas.

Ingo Payments, a proven leader in account funding, transfer, and payout solutions—known as "money mobility"—is proud to announce the selection of Marqeta, the global modern card issuing platform that enables embedded finance solutions for the world’s innovators, as its issuer processing partner. This partnership marks a significant step forward in Ingo’s mission to deliver innovative instant account issuing and ecosystem-driven financial services for its clients.

– FDA meeting to align on myositis registrational trial designs for rese-cel in 1H25 on track –

Rapid Enrollment and Dosing of First Patients in PRECISE-AD Trial Underscores the Unmet Need for Better Treatment Options for Alzheimer’s Disease

Completed enrollment of Phase 2 AMPLIFY-7P randomized study; disease-free survival (“DFS”) event-driven interim analysis expected in Q3 2025

WATERTOWN, Mass., March 31, 2025 (GLOBE NEWSWIRE) -- Remix Therapeutics (Remix), a clinical-stage biotechnology company developing small molecule therapies to modulate RNA processing and address the underlying drivers of disease, today announced that Peter Smith, Ph.D., Co-Founder and Chief Executive Officer of Remix, will present a corporate overview at the Stifel 2025 Virtual Targeted Oncology Forum on Tuesday, April 8, 2025, at 1:00 p.m. ET.

WALTHAM, Mass., March 31, 2025 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biotechnology company focused on the development of T cell receptor (TCR)-engineered T cell (TCR-T) therapies for the treatment of patients with cancer, today announced that the Company will participate in a fireside chat at the 24th Annual Needham Virtual Healthcare Conference on Monday, April 7, 2025 at 9:30 a.m. Eastern Time.

The OviTex PRS portfolio now includes a larger option than any human acellular dermal matrix product on the market

SEATTLE, March 31, 2025 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. ("Perspective" or the "Company") (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatment applications for cancers throughout the body, today announced that members of its senior leadership team will participate in and be available for one-on-one meetings with investors at the following upcoming investor conferences.

AVA6000 Phase 1b expansion cohorts enrolling with data targeted for later in 2025

SAN DIEGO, March 31, 2025 (GLOBE NEWSWIRE) -- Gyre Therapeutics (“Gyre”) (Nasdaq: GYRE), an innovative, commercial-stage biotechnology company focused on organ fibrosis, today announced that the National Medical Products Administration (NMPA) of the People’s Republic of China (“PRC”) has approved its clinical trial application for a potential new indication for pirfenidone in oncology-related pulmonary complications. The trial will evaluate pirfenidone capsules for the treatment of radiation-induced lung injury (RILI), with or without immune-related pneumonitis (CIP).

TORONTO, March 31, 2025 (GLOBE NEWSWIRE) -- Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FRA: 0K91) (“Quantum BioPharma” or the “Company”) is pleased to announce that it has closed the final tranche (“Final Tranche”) of the offering announced on December 5, 2024 (the “December 5 NR”) as amended on January 20, 2025, and based on the better terms announced on March 7, 2025 (the “March 7 NR”). The Company issued 2,420 Debenture Units (as defined in the December 5 NR, as amended by the March 7 NR) for $2,420,000 as part of this Final Tranche bringing the total amount raised to $5 million. The Company will use the proceeds to advance the research and development of its innovative drug candidates, advancing commercialization and monetization of certain assets, and for general working capital purposes. Management now believes there is enough cash to execute on these advances until at least the first quarter of 2027.

-- At All Doses Evaluated, VAX-24 Was Well-Tolerated and Demonstrated a Safety and Tolerability Profile Similar to Prevnar 20® (PCV20) --

Report includes tenfold revenue growth and significant gross margin expansion

ALMATY, Kazakhstan, March 31, 2025 (GLOBE NEWSWIRE) -- Joint Stock Company Kaspi.kz (Nasdaq: KSPI) announces that the following resolutions were duly passed at its Annual General Meeting on 28 March 2025:

Statement Pursuant to Section 19(a) of the Investment Company Act of 1940

The seventh edition of the International Meeting on Pulmonary Hypertension Clinical Treatment (IMPAHCT), organized by the pharmaceutical company Ferrer, gathered over 150 experts in pulmonology and cardiology from more than 30 countries in Barcelona this past weekend. The event reaffirmed the clinical community’s commitment to multidisciplinary and international collaboration to improve the treatment of pulmonary hypertension (PH), a serious condition affecting 1% of the population. PH is often accompanied by debilitating symptoms and an increased risk of mortality.

SAN DIEGO, March 31, 2025 (GLOBE NEWSWIRE) -- LPL Financial Holdings Inc. (NASDAQ: LPLA) (together with its subsidiaries, including LPL Financial LLC, “LPL Financial” or “LPL”) today announced that it has commenced an underwritten public offering of $1.5 billion of its common stock.

The "GCC Data Center Market - Investment Analysis & Growth Opportunities 2025-2030" report has been added to ResearchAndMarkets.com's offering.

ATLANTA, March 31, 2025 (GLOBE NEWSWIRE) -- Descartes Systems Group (Nasdaq:DSGX) (TSX:DSG), the global leader in uniting logistics-intensive businesses in commerce, announced that international freight forwarder Skypace is using the Descartes Global Price Management™ (GPM) solution to populate its self-service quote-to-book platform with accurate shipping rates and provide a digital-first experience for its growing customer base. 

Company to Host Business Update Call at 4:30 PM ET on Wednesday, April 9, 2025

Appalachian Mountain Energy, the joint venture, will drill new wells and rework existing wells currently owned and operated by Mountain V Oil & Gas across all 300,000 surface and mineral acres across the Appalachian Basin and Permian Basin that are currently held by production by Mountain V Oil & Gas.

Annual Revenue Increased 88.66%, While Annual Net Income Increased 663.27%

MARKHAM, ON / ACCESS Newswire / March 31, 2025 / iFabric Corp. ("iFabric" or the "Company") (TSX:IFA)(OTCQX:IFABF), today announced its audited results for its fourth quarter and fiscal year ended December 31, 2024 ("2024"), with record revenues and strong profitability. With effect from October 1, 2022, the Company changed its financial year end to December 31. Accordingly, the comparative figures for fiscal 2023 are presented for a period of 15 months, compared to 12 months in fiscal 2024.

Vancouver, British Columbia--(Newsfile Corp. - March 31, 2025) - Heliostar Metals Ltd. (TSXV: HSTR) (OTCQX: HSTXF) (FSE: RGG1) ("Heliostar" or...

ICON plc, (NASDAQ: ICLR) a world-leading clinical research organisation powered by healthcare intelligence, today announced that it will release its financial results for the first quarter 2025 after the market closes on Wednesday, April 30, 2025. The company will hold a conference call and webcast to discuss its financial results and performance on Thursday, May 1, 2025 at 8:00am ET.

Cool Company Ltd. (“CoolCo” or the “Company”) (NYSE: CLCO / CLCO.OL) announces that it has filed its Form 20-F for the year ended December 31, 2024 with the Securities and Exchange Commission (SEC) in the U.S.

Ares Management Corporation (NYSE:ARES) (“Ares”) announced today that Joel Holsinger, Partner and Co-Head of Ares’ Alternative Credit strategy, was appointed to the Board of Directors of the Ares Charitable Foundation (the “Ares Foundation”) to serve as Co-Chair alongside current Chair, Michael Arougheti, Chief Executive Officer of Ares.

Spectrum Vascular (“Spectrum” or the “Company”), a provider of vascular access and medication management products designed to reduce health care-acquired infections, announced today a strategic investment by an affiliate of New York-based private investment firm SK Capital Partners (“SK Capital”).